Masimo Co. (NASDAQ:MASI) Given Average Recommendation of “Moderate Buy” by Analysts

Masimo Co. (NASDAQ:MASI) has been given an average recommendation of “Moderate Buy” by the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $144.67.

Several equities research analysts recently commented on the company. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Friday. Piper Sandler boosted their price target on shares of Masimo from $160.00 to $165.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th.

Masimo Stock Performance

NASDAQ:MASI opened at $121.42 on Monday. Masimo has a twelve month low of $75.22 and a twelve month high of $153.93. The company has a quick ratio of 1.15, a current ratio of 2.09 and a debt-to-equity ratio of 0.55. The stock’s 50-day simple moving average is $115.01 and its 200 day simple moving average is $124.98. The firm has a market capitalization of $6.46 billion, a PE ratio of 82.60 and a beta of 0.98.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.77 by $0.09. The business had revenue of $496.30 million for the quarter, compared to the consensus estimate of $493.92 million. Masimo had a net margin of 3.94% and a return on equity of 14.07%. The firm’s revenue was up 9.0% compared to the same quarter last year. During the same period last year, the company earned $0.62 EPS. On average, analysts anticipate that Masimo will post 3.87 EPS for the current fiscal year.

Institutional Investors Weigh In On Masimo

A number of hedge funds have recently made changes to their positions in the business. Riverview Trust Co bought a new position in shares of Masimo in the first quarter worth approximately $25,000. GAMMA Investing LLC raised its holdings in shares of Masimo by 75.0% during the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 111 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Masimo by 851.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 295 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 264 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 200 shares during the period. Finally, Parallel Advisors LLC grew its position in Masimo by 48.3% during the 4th quarter. Parallel Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $52,000 after acquiring an additional 145 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.